Triple-Peptide Nanoparticle Delivers Chemo + Gene Therapy for Head and Neck Cancer, Outperforming Onivyde
pH-sensitive nanoparticles decorated with three functional peptides delivered irinotecan plus miR-200 gene therapy to head and neck cancer, outperforming commercial Onivyde in mice.
Quick Facts
What This Study Found
Triple-peptide pH-responsive nanoparticles co-delivering irinotecan and miR-200 outperformed Onivyde in a head and neck cancer mouse model by simultaneously targeting EMT, MDR, and Wnt pathways.
Key Numbers
Outperformed Onivyde; regulated Wnt/beta-catenin, MDR, EMT pathways; 3 peptide types used for targeting
How They Did This
Nanoparticle design with pH-cleavable PEG + 3 peptides; physicochemical characterization; SAS cell cytotoxicity and uptake; pathway analysis (Wnt, MDR, EMT); in vivo SAS tumor-bearing mouse efficacy and safety studies; compared to Onivyde.
Why This Research Matters
Head and neck cancers resist treatment through EMT and drug resistance pathways. Combining chemo with gene therapy in a single smart nanoparticle attacks both problems simultaneously.
The Bigger Picture
Peptide-decorated nanoparticles that respond to tumor acidity represent the frontier of precision cancer therapy — delivering multiple treatments exactly where needed while sparing healthy tissue.
What This Study Doesn't Tell Us
Mouse tumor model with single cancer type (tongue SCC); complex multi-component formulation may be hard to manufacture at scale; long-term toxicity not assessed.
Questions This Raises
- ?Can this multi-peptide nanoparticle platform be adapted for other cancer types?
- ?What are the manufacturing challenges for a 3-peptide + PEG + 2-drug nanoparticle?
- ?Would this approach work in combination with immunotherapy?
Trust & Context
- Key Stat:
- Outperformed Onivyde Triple-peptide nanoparticle co-delivery of irinotecan + miR-200 exceeded commercial Onivyde efficacy and safety
- Evidence Grade:
- Moderate — comprehensive preclinical study with in vivo efficacy comparison to an approved drug, but single cancer model.
- Study Age:
- Published in 2020; combination chemo/gene therapy nanoparticles remain an active development area.
- Original Title:
- PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.
- Published In:
- Theranostics, 10(15), 6695-6714 (2020)
- Authors:
- Lo, Yu-Li(3), Chang, Chih-Hsien(2), Wang, Chen-Shen(2), Yang, Muh-Hwa, Lin, Anya Maan-Yuh, Hong, Ci-Jheng, Tseng, Wei-Hsuan
- Database ID:
- RPEP-04965
Evidence Hierarchy
Frequently Asked Questions
How do the nanoparticles know to release drugs at the tumor?
The PEG coating dissolves in the acidic environment around tumors (pH ~6.5), exposing the targeting and cell-penetrating peptides that deliver the drugs specifically into cancer cells.
Why combine chemo with gene therapy?
Irinotecan kills cancer cells while miR-200 blocks the escape routes (EMT and drug resistance) that cancer uses to survive treatment. Together they're more effective than either alone.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-04965APA
Lo, Yu-Li; Chang, Chih-Hsien; Wang, Chen-Shen; Yang, Muh-Hwa; Lin, Anya Maan-Yuh; Hong, Ci-Jheng; Tseng, Wei-Hsuan. (2020). PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.. Theranostics, 10(15), 6695-6714. https://doi.org/10.7150/thno.45164
MLA
Lo, Yu-Li, et al. "PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer.." Theranostics, 2020. https://doi.org/10.7150/thno.45164
RethinkPeptides
RethinkPeptides Research Database. "PEG-coated nanoparticles detachable in acidic microenvironme..." RPEP-04965. Retrieved from https://rethinkpeptides.com/research/lo-2020-pegcoated-nanoparticles-detachable-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.